Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Trial ID or NCT#
NCT04260698
Status
NOT RECRUITING
Purpose
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Official Title
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 12 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Patients must be at least 12 years of age - Applicable disease criteria - Patients must have one or two partially HLA-matched CBUs - Back-up stem cell source - Sufficient physiological reserves - Females of childbearing potential agree to use appropriate method of contraception - Signed written informed consent
Exclusion Criteria:
- - Extensive bone marrow fibrosis - Donor specific anti-HLA antibodies - Pregnancy - Medically unsuitable for transplant
Investigator(s)
Andrew Rezvani, M.D.
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Medical oncologist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Contact us to find out if this trial is right for you.
Contact
Khanh Nguyen
650-721-2372
View on ClinicalTrials.gov
